Literature DB >> 11831726

Nef and LTR sequence variation from sequentially derived human immunodeficiency virus type 1 isolates.

T McNearney1, Z Hornickova, A Templeton, A Birdwell, M Arens, R Markham, A Saah, L Ratner.   

Abstract

Variation in HIV-1 nef and LTR DNA sequences was assessed longitudinally during disease progression in four HIV-1-infected subjects. Point mutations were found among quasispecies obtained at a single time point in each individual, with increasing diversity with disease progression in two of three patients for whom sufficient data were available for analysis. Deletions and rearrangements were more common in late than early stages of disease. Continued sequence evolution in HIV-1 quasispecies with nef deletions along with coexistence of nef-bearing quasispecies suggest that nef-deleted quasispecies are capable of replication in vivo, possibly complemented by quasispecies lacking such deletions and/or by adaptation to a specialized niche within the patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 11831726     DOI: 10.1006/viro.1995.1166

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Human immunodeficiency virus type 1 long terminal repeat variants from 42 patients representing all stages of infection display a wide range of sequence polymorphism and transcription activity.

Authors:  M C Estable; B Bell; A Merzouki; J S Montaner; M V O'Shaughnessy; I J Sadowski
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

2.  Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor.

Authors:  R Salvi; A R Garbuglia; A Di Caro; S Pulciani; F Montella; A Benedetto
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Genotypic and phenotypic heterogeneity in the U3R region of HIV type 1 subtype C.

Authors:  Jessica M Mates; Surender B Kumar; Jose Bazan; Megan Mefford; Igor Voronkin; Samuel Handelman; Victor Mwapasa; William Ackerman; Daniel Janies; Jesse J Kwiek
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-12       Impact factor: 2.205

4.  Genetic drift can dominate short-term human immunodeficiency virus type 1 nef quasispecies evolution in vivo.

Authors:  U Plikat; K Nieselt-Struwe; A Meyerhans
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 5.  BK polyomavirus diversity-Why viral variation matters.

Authors:  Jason T Blackard; Stella M Davies; Benjamin L Laskin
Journal:  Rev Med Virol       Date:  2020-03-03       Impact factor: 6.989

6.  Identification of a replication-competent pathogenic human immunodeficiency virus type 1 with a duplication in the TCF-1alpha region but lacking NF-kappaB binding sites.

Authors:  L Zhang; Y Huang; H Yuan; B K Chen; J Ip; D D Ho
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

7.  Extensive diversification of human immunodeficiency virus type 1 subtype B strains during dual infection of a chimpanzee that progressed to AIDS.

Authors:  Q Wei; P N Fultz
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Naturally occurring human immunodeficiency virus type 1 long terminal repeats have a frequently observed duplication that binds RBF-2 and represses transcription.

Authors:  M C Estable; B Bell; M Hirst; I Sadowski
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

9.  Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes.

Authors:  Justin Stebbing; Dimitra Bourboulia; Margaret Johnson; Stephen Henderson; Ian Williams; Natalie Wilder; Mervyn Tyrer; Mike Youle; Nesrina Imami; Toru Kobu; Wolfgang Kuon; Joachim Sieper; Frances Gotch; Chris Boshoff
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

10.  Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease.

Authors:  F Kirchhoff; P J Easterbrook; N Douglas; M Troop; T C Greenough; J Weber; S Carl; J L Sullivan; R S Daniels
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.